Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Key amyloidosis data from ASH 2019

Morie Gertz • 7 Dec 2019
ASH 2019
Amyloidosis Rare Diseases Cyclophosphamide Dexamethasone Ixazomib

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, highlights key amyloidosis data from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. In particular, the phase III trial of ixazomib, dexamethasone, and cyclophosphamide in patients with light chain (AL) amyloidosis.

More from Morie Gertz

Amyloidosis Sessions: Highlights from ISA 2022
Morie Gertz et al. • 6 Sep 2022
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis 1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
The role of allogeneic transplantation in patients with multiple myeloma 1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
The importance of identifying AH amyloidosis in patients with normal free light chain levels 1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals